MoonLake Immunotherapeutics (MLTX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$11.86

From 52W high−49.73%

Volume516291.00

Market cap$948.09M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$11.86

From 52W high

−49.73%

Volume

516291.00

Market cap

$948.09M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.0x

P/E (TTM)

—

RSI (14)

44.1

MomentumView details →

1D Return

−4.79%

YTD Return

−16.20%

SummaryUpdated Jun 1, 2026

MoonLake Immunotherapeutics (NASDAQ:MLTX) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Zug, Switzerland. The company went public in October 2020 and focuses on developing innovative therapies for inflammatory conditions. MoonLake is currently advancing its lead candidate, Sonelokimab, through multiple Phase II clinical trials targeting various autoimmune and inflammatory diseases.

Ask drillr about MoonLake Immunotherapeutics →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−61.58%

ROA (TTM)

−45.94%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−38.49%

FCF YoY

−35.03%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−86.77%

EBITDA YoY

−41.34%

MomentumView details →

1D Return

−4.79%

YTD Return

−16.20%

1Y Return

+4.30%

RSI (14)

44.1

vs 50D SMA

−10.01%

vs 200D SMA

−32.60%

Capital & dividendView details →

Debt/Equity

0.24x

Current Ratio

12.56x

Quick Ratio

12.56x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.93

EPS Surprise

−20.78%

Beats (12Q)

6/12

Next Q EPS Est

−$0.81

Avg Surprise (4Q)

−5.23%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−263.67M

Op. CF (TTM)

−225.18M

Next earningsNov 4, 2026 →

Latest newsMore news →

MoonLake Immunotherapeutics reported its third-quarter 2026 financial results.5h ago

MoonLake Immunotherapeutics shares traded higher, with session volume of 4.20 million shares versus an average volume of 1.494 million.13d ago

Similar companies

Syndax Pharmaceuticals, Inc.SNDX ORIC Pharmaceuticals, Inc.ORIC Inventiva S.A.IVA Rigel Pharmaceuticals, Inc.RIGL Savara Inc.SVRA Jade Biosciences, Inc.JBIO Find similar companies →

Latest newsMore news →

MoonLake Immunotherapeutics reported its third-quarter 2026 financial results.5h ago MoonLake Immunotherapeutics shares traded higher, with session volume of 4.20 million shares versus an average volume of 1.494 million.13d ago